Colorectal cancer (CRC) is the third most commonly diagnosed cancer in males and the second most commonly diagnosed cancer in females worldwide.1 Great advancements have been made in CRC treatments, including surgery, radiochemotherapy and the development of monoclonal antibodies against vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). Here, VEGFA is linked to colorectal carcinoma.